RYE, N.Y., Dec. 2, 2010 /PRNewswire/ -- Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that four additional sites across the country are now participating in Phase III clinical trials for the company's autism treatment CM-AT. The new trial sites are:
- Institute for Behavioral Medicine, Smyrna, Georgia
- Cyn3rgy Research, Gresham, Oregon
- Westside Medical Clinic, Clinton, Utah
- Oklahoma University Physician's Child Study Center, Oklahoma City
There are now a total of 19 sites nationally conducting Phase III trials for Curemark's autism therapy. The study is targeting a total enrollment of 170 children.
"We have been extremely pleased with the response and the level of participation in the CM-AT autism study," said Dr. Joan Fallon, Curemark founder and CEO. "Enrollment is continuing to proceed well at our other trial sites throughout the country."
CM-AT, which has received Fast Track status from the FDA, targets enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the availability of amino acids, the building blocks of chemicals essential for brain function. If approved, CM-AT will be one of the first therapies to address the underlying physiology of autism.
For information on enrolling in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointest